CSIMarket
 
Sight Sciences Inc   (NASDAQ: SGHT)
Other Ticker:  
 
 
Price: $2.7400 $0.18 7.031%
Day's High: $2.77 Week Perf: -1.08 %
Day's Low: $ 2.50 30 Day Perf: -13.02 %
Volume (M): 259 52 Wk High: $ 8.45
Volume (M$): $ 709 52 Wk Avg: $5.29
Open: $2.58 52 Wk Low: $2.50



 Market Capitalization (Millions $) 138
 Shares Outstanding (Millions) 50
 Employees 413
 Revenues (TTM) (Millions $) 79
 Net Income (TTM) (Millions $) -50
 Cash Flow (TTM) (Millions $) -26
 Capital Exp. (TTM) (Millions $) 1

Sight Sciences Inc
Sight Sciences Inc. is a medical technology company focused on designing and developing non-surgical treatments for patients with vision-threatening eye diseases. The company's primary aim is to improve surgical outcomes and enhance patient quality of life through innovative and minimally invasive solutions. Its products include the OMNI Surgical System, a comprehensive platform for the treatment of glaucoma, as well as the TearCare System, which provides a novel approach to treating evaporative dry eye. Sight Sciences Inc. is known for its commitment to advancing ophthalmic care and addressing unmet needs in the field.


   Company Address: 4040 Campbell Ave Menlo Park 94025 CA
   Company Phone Number: 266-1144   Stock Exchange / Ticker: NASDAQ SGHT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
GKOS   -4.38%    
MMM   -0.6%    
ABBV        2.21% 
ACU   -0.42%    
• View Complete Report
   



Announcement

Revamping Eye Care Cost-Effective Solutions for Meibomian Gland Disease Revealed

Published Thu, Dec 19 2024 9:05 PM UTC

Cost-Effective Innovations in Ocular Health: Budget Impact Analysis of Sight Sciences? TearCare System for Meibomian Gland DiseaseThe field of ophthalmology is on the cusp of transformation with the innovative introduction of the TearCare System by Sight Sciences, designed specifically for the treatment of Meibomian Gland Disease (MGD). As the prevalence of MGD continues to...

Management Changes

Vision on the Brink: Sight Sciences Leadership Shuffle Amid Financial Headwinds

Published Thu, Nov 7 2024 9:04 PM UTC

In a notable shift aimed at reinvigorating its strategic direction, Sight Sciences Inc. has recently appointed MK Raheja as Executive Vice President of Research and Development, and Brenton Taylor as Executive Vice President of Operations. These appointments signal the company?s renewed commitment to innovating in the eyecare landscape, particularly in light of the staggeri...

Clinical Study

Evaluating the Clinical Efficacy of TearCare Treatment for Dry Eye Disease Amidst the Financial Landscape of Sight Sc...

Published Mon, Oct 14 2024 8:05 PM UTC

Dry eye disease (DED) remains a significant public health concern, impacting the quality of life of individuals globally. Recent advancements in treatment options, particularly investigator-initiated clinical trials involving TearCare, present a promising outlook for enhanced patient outcomes. However, these clinical successes occur against a backdrop of ongoing financial ch...

Announcement

Sight Sciences Announces Strong Q2 2024 Results, Expands Financial Outlook Amid Growing Demand for Innovative Ey...

Published Thu, Aug 1 2024 8:06 PM UTC

Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance MENLO PARK, Calif., Aug. 01, 2024 Sight Sciences, Inc. (Nasdaq: SGHT), a pioneering eyecare technology company, has released its financial results for the second quarter ended June 30, 2024. The company is dedicated to developing and commercializing innovative inte...

Stocks on the Move

Sight Sciences Inc A Rollercoaster Ride of Market Performance and Insider Activity

Published Fri, Jul 12 2024 11:07 AM UTC

Sight Sciences Inc (NASDAQ: SGHT) has garnered significant attention recently, with a flurry of insider activity and market performance that has left investors intrigued. This article delves into the key events surrounding Sight Sciences Inc and its implications for potential investors. Despite various ups and downs, Sight Sciences Inc has managed to outperform the market ye...







Sight Sciences Inc's Segments
Surgical Glaucoma    93.6 % of total Revenue
Dry Eye    7.66 % of total Revenue

  Sight Sciences Inc Outlook

On March 7 2024 the Sight Sciences Inc provided following guidance

Sight Sciences Inc., a leading eyecare technology company, recently announced its financial results for the fourth quarter and full year of 2023. The company, known for developing and commercializing cutting-edge interventional technologies aimed at revolutionizing patient care and enhancing lives, reported strong performance for the period ending December 31, 2023.

In addition to sharing its financial results, Sight Sciences also provided financial guidance for the entire year of 2024. The company aims to continue its trajectory of success and growth, building on its innovative technologies and commitment to improving patient outcomes.

The announcement underscores Sight Sciences' dedication to...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com